Actively Recruiting
EyeConic Study to Identify Patients for Cone-Optogenetics Vision Restoration Using Optical Coherence Tomography
Led by Institute of Molecular and Clinical Ophthalmology Basel · Updated on 2025-07-31
1000
Participants Needed
9
Research Sites
N/A
Total Duration
AI-Summary
What this Trial Is About
This research focuses on inherited retinal dystrophies IRDs, a group of eye conditions where cone cells in the retina lose their ability to sense light but may remain alive in a dormant state. The study aims to prepare for the first human trial of cone optogenetics, a technique to restore vision by reactivating these dormant cones. To do this, researchers are conducting a worldwide multicenter imaging study called EyeConic to identify eligible patients and estimate how many low vision patients have remaining cone cells. The study uses macular optical coherence tomography OCT, a detailed imaging method of the retina, to gather data from both patients with IRDs and control participants with normal eye health. This observational study involves collecting and analyzing OCT images to assess central retinal volume and identify the presence of dormant cones. No treatments or interventions are given, as the study focuses on imaging and data collection. Participants will undergo OCT imaging to measure their retinal structure, particularly central retinal volume, which is the primary outcome. Researchers will review this baseline data to understand the proportion of patients with surviving cone cells. The study includes both patients with low vision due to IRDs and healthy controls. Participation involves one imaging session lasting about 10 minutes. The study is ongoing with an expected completion by December 2026.
CONDITIONS
Brief Title
EyeConic: Qualification for Cone-Optogenetics
Research Team
L
Lucas Janeschitz-Kriegl, MD
T
Tiana Koottungal
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here